CorMedix Reaffirms 2026 Revenue Guidance And Reports Q3 Cash Position
CorMedix announced $355 million in cash and reaffirmed 2026 revenue guidance of $325M-$345M, anticipating a DefenCath reimbursement increase for Q1 2027. Management indicated that Add-on projected rates in 2027 will exceed current levels.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed